AstroStem vs RB-ADSC

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Mesenchymal stem cell therapy · full Alzheimer's Disease pipeline

AstroStem

Developed by Nature Cell Co., Ltd. and partners

Phase 2 in Alzheimer's DiseaseCell therapy (autologous adipose MSC)
Weak signal

NCT03117738 · Phase 1/2 · completed

This trial was randomized and triple-blinded with a placebo control, which is a strong design foundation, but it enrolled only 21 participants (11 vs 10, with substantial dropout leaving just 7 per arm for the cognitive endpoint), making it severely underpowered. The primary cognitive endpoint (ADAS-Cog change) numerically favored placebo over AstroStem, and no p-value or confidence interval was reported for either primary outcome, so the primary comparison cannot be called a success for the drug.

Reported efficacy

Treatment Related Adverse Events (30 Weeks); ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale) (Baseline and 30 Weeks): ADAS-Cog change at Week 30: 5.9 (SD 6.8) AstroStem vs 3.0 (SD 5.4) placebo; n=7 vs 7. (unclear)

Result source: NCT03117738

RB-ADSC

Developed by Regeneration Biomedical, Inc.

Phase 2 in Alzheimer's DiseaseCell therapy (autologous adipose stem cell)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2028 · NCT07373067 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAstroStemRB-ADSC
CDR-SB, change1.3 vs 0.9+0.4 vs placebowk 30 · n 7NCT03117738—Not reported
ADAS-Cog11, change—Not reported—Not reported
ADCS-ADL, change-4.4 vs -4.7+0.3 vs placebowk 30 · n 7NCT03117738—Not reported
MMSE, change-3.4 vs -1.4−2 vs placebowk 30 · n 7NCT03117738—Not reported
Amyloid PET, change (centiloids)—Not reported—Not reported

CDR-SB, change

AstroStem
1.3 vs 0.9+0.4 vs placebowk 30 · n 7NCT03117738
RB-ADSC
—Not reported

ADAS-Cog11, change

AstroStem
—Not reported
RB-ADSC
—Not reported

ADCS-ADL, change

AstroStem
-4.4 vs -4.7+0.3 vs placebowk 30 · n 7NCT03117738
RB-ADSC
—Not reported

MMSE, change

AstroStem
-3.4 vs -1.4−2 vs placebowk 30 · n 7NCT03117738
RB-ADSC
—Not reported

Amyloid PET, change (centiloids)

AstroStem
—Not reported
RB-ADSC
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

RB-ADSC: no structured comparison results are available for Alzheimer's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. AstroStem: 3 of 4 rows · RB-ADSC: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAstroStem
Dropout rate
36.4%
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
Discontinued due to AEs
—
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
Serious AEs
27.3%
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
Most frequent reported AEs
abnormal loss of weight 9.1% (placebo 0%)
dehydration 9.1% (placebo 10%)
dysphagia 9.1% (placebo 0%)
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

AstroStem

ADAS-Cog 5.9 vs 3 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
MMSE -3.4 vs -1.4 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
CDR-SB 1.3 vs 0.9 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
NPI -1.4 vs -5.7 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
GDS -0.3 vs 0.3 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
ADCS-ADL -4.4 vs -4.7 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AstroStem's landscape · RB-ADSC's landscape